Hypoglycemic risk of insulinotropic drugs;Hypoglykämie bei insulinotropen substanzen

Medizinische Monatsschrift fur Pharmazeuten

Volumn 32, Issue 12, 2009, Pages 453-458

  Böhm, Ruwen ^a   Cascorbi, Ingolf ^a   Herdegen, Thomas ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; NATEGLINIDE; REPAGLINIDE; TOLBUTAMIDE;

CARDIOVASCULAR DISEASE; DIABETIC PATIENT; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; SYMPTOM;

BLOOD GLUCOSE; GLYBURIDE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; RISK; SULFONYLUREA COMPOUNDS;

EID: 73449142170     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Henquin JC. Alternative pathway of beta-cell stimulation: possible therapeutic targets? Medicographia 2005;27:313-319
2. + channels. Diabetes 2004;53(Suppl 2):S104-12.
3. Ashcroft SJH. The β-Cell KATP Channel. J Membr Biol 2000;176:187-206.
4. Remko M. Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. J Mol Structure: Theochem 2009;897:73-82.
5. Mark M. Sulfonylharnstoffe und Glinide. Pharm Unserer Zeit 2002;31:252-262
6. Gribble F, Reimann F. Differential selectivity of insulin secretagogues. J Diabetes Complications 2003;17:11-15
7. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, et al. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25:1271-1276
8. Wolffenbuttel BH, et al. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999;22:463-467 (Pubitemid 29106906)
9. Marbury T, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-166 (Pubitemid 29202125)
10. Rendell M. The role of sulfonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-1358 (Pubitemid 38916346)
11. Holstein A, et al. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metab Res Rev 2001;17:467-473 (Pubitemid 34030749)
12. Holstein A, et al. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 2003;59:91-97 (Pubitemid 36793719)
13. Gribble FM, Reimann F. Sulphonylurea action revisited: the post- cloning era. Diabetologia 2003;36:875-891 (Pubitemid 36961311)
14. Shorr RI, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996;44:751-755
15. Van Staa T, et al. Rates of hypoglycemia in users of sulfonylureas. J Clinical Epidemiol 1997;50:735-741
16. Papa G, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people. Diabetes Care 2006;29:1918-1920
17. Vlckova V, et al. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009;32:409-418
18. Bericht über unerwünschte Arzneimittelwirlcungen (auch Verdachtsfälle) an die Arzneimittelkommission der ABDA oder Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) gemäß der Berufsordnungen für Apotheker und Ärzte.
19. Bate A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315-321 (Pubitemid 28328016)